有统计数据显示,今年1-9月中国创新药出海合同总金额超1000亿美元,同比增长170%。有机构表示,仍然坚定看好创新产业链长牛行情。创新药出海已成趋势,年底预期将有更多BD兑现,仍然坚定看好创新板块行情,重仓BD确定性。据悉,进入10月,创新药BD交易仍然火热。如10月8日诺诚健华宣布与海外生物药企Zenas达成合作,将其自身免疫领域小分子药物奥布替尼进行海外授权,协议总金额超过20亿美元,进一步...
Source Link有统计数据显示,今年1-9月中国创新药出海合同总金额超1000亿美元,同比增长170%。有机构表示,仍然坚定看好创新产业链长牛行情。创新药出海已成趋势,年底预期将有更多BD兑现,仍然坚定看好创新板块行情,重仓BD确定性。据悉,进入10月,创新药BD交易仍然火热。如10月8日诺诚健华宣布与海外生物药企Zenas达成合作,将其自身免疫领域小分子药物奥布替尼进行海外授权,协议总金额超过20亿美元,进一步...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.